ARCTURUS THERAPEUTICS HOLDINGS INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARCTURUS THERAPEUTICS HOLDINGS INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $16.00K, a 91.79% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $640.00K, a 5718.18% increase year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $274.00K, a 88.60% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $195.00K, a 91.09% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. stock issued during period, value, stock options exercised for fiscal 2025 was $1.11M, a 76.58% decline from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. stock issued during period, value, stock options exercised for fiscal 2024 was $4.74M, a 77.51% increase from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. stock issued during period, value, stock options exercised for fiscal 2023 was $2.67M, a 54.22% increase from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. stock issued during period, value, stock options exercised for fiscal 2022 was $1.73M, a 91.80% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-03-31 | $16.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $1.11M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $640.00K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $274.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $195.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $4.74M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $11.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $2.40M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $2.19M 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $2.67M 10-K · filed 2026-03-03 | |
| 2023-09-30 | $1.23M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $94.00K 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $1.73M 10-K · filed 2025-03-06 | |
| 2022-09-30 | $369.00K 10-Q · filed 2023-11-14 | $1.19M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $257.00K 10-Q · filed 2023-11-14 | $1.00M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $336.00K 10-Q · filed 2023-11-14 | $825.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $902.00K 10-K · filed 2024-03-14 |
| 2021-09-30 | $177.00K 10-Q · filed 2022-11-09 | $1.94M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $82.00K 10-Q · filed 2022-11-09 | $2.40M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-03-31 | $413.00K 10-Q · filed 2022-11-09 | $3.02M derived: sum of 4 quarters · filed 2022-11-09 |
| 2020-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $2.73M 10-K · filed 2022-03-01 |
| 2020-09-30 | $645.00K 10-Q · filed 2021-11-09 | $1.55M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $698.00K 10-Q · filed 2021-08-10 | $954.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $118.00K 10-Q · filed 2021-05-10 | $257.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $139.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $49.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $1.00K 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $371.00K 10-K · filed 2021-03-01 |
| 2018-09-30 | $20.00K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $47.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |